/wp-content/uploads/iEcure_logo.png
0
0
David Anderson
/wp-content/uploads/iEcure_logo.png
David Anderson2023-03-21 18:54:482023-03-24 17:25:20European Commission Grants Orphan Designation for iECURE’s Lead Product Candidate GTP-506 for the Treatment of Ornithine Transcarbamylase (OTC) Deficiency
/wp-content/uploads/iEcure_logo.png
0
0
David Anderson
/wp-content/uploads/iEcure_logo.png
David Anderson2023-03-15 19:15:252023-03-23 14:57:07iECURE Appoints Gabriel M. Cohn, M.D., as Chief Medical Officer
/wp-content/uploads/iEcure_logo.png
0
0
David Anderson
/wp-content/uploads/iEcure_logo.png
David Anderson2022-11-30 00:00:412023-03-24 17:26:58iECURE Raises $65 Million to Advance In Vivo Gene Editing Programs for the Treatment of Rare Pediatric Liver Diseases
/wp-content/uploads/iEcure_logo.png
0
0
David Anderson
/wp-content/uploads/iEcure_logo.png
David Anderson2022-10-19 08:00:312023-03-24 17:28:32Preclinical Data from iECURE’s GTP-506 Demonstrates Potential for the Treatment of Ornithine Transcarbamylase (OTC) Deficiency
/wp-content/uploads/iEcure_logo.png
0
0
David Anderson
/wp-content/uploads/iEcure_logo.png
David Anderson2022-09-02 20:04:532023-03-24 17:30:23iECURE Receives FDA Orphan Drug Designation for GTP-506, an Investigational Gene Editing Product Candidate for the Treatment of Ornithine Transcarbamylase (OTC) Deficiency
/wp-content/uploads/iEcure_logo.png
0
0
eallison
/wp-content/uploads/iEcure_logo.png
eallison2022-08-22 19:18:032023-03-24 17:37:04iECURE Receives FDA Rare Pediatric Disease Designation for GTP-506, an Investigational Gene Editing Product Candidate for the Treatment of Ornithine Transcarbamylase (OTC) Deficiency
/wp-content/uploads/iEcure_logo.png
0
0
David Anderson
/wp-content/uploads/iEcure_logo.png
David Anderson2022-05-25 05:00:362022-05-25 08:00:43iECURE Enters Agreement with Center for Breakthrough Medicines (CBM) to Supply Materials for Future Clinical Programs
/wp-content/uploads/iEcure_logo.png
0
0
David Anderson
/wp-content/uploads/iEcure_logo.png
David Anderson2022-05-18 08:00:012022-05-18 08:16:53Nonhuman Primate Data from iECURE’s Knock-in In Vivo Gene Editing Approach for Deadly Urea Cycle Disorder to be Presented in Presidential Symposium at ASGCT 2022
/wp-content/uploads/iEcure_logo.png
0
0
David Anderson
/wp-content/uploads/iEcure_logo.png
David Anderson2022-05-02 19:02:112022-05-10 20:51:39iECURE Announces Presentation of Data on its Gene Editing Approach at the American Society of Cell and Gene Therapy Annual Meeting
/wp-content/uploads/iEcure_logo.png
0
0
David Anderson
/wp-content/uploads/iEcure_logo.png
David Anderson2022-04-25 07:00:042022-05-10 20:48:21iECURE Appoints George Diaz, M.D., Ph.D., as VP, Therapeutic Area Lead for Urea Cycle Disorders
Scroll to top